Bioiberica reinforces their presence in Russia
Bioiberica’s joint healthcare division and heparin business unit participated at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
The Russian pharmaceutical market is growing at a 10 percent annual rate, and is expected to reach 25 Billion Dollars by 2018
The second edition of the CPhI Rusia fair, held in Moscow on 27-29 April, brought together world leading firms specializing in the manufacture and distribution of active ingredients and finished pharmaceutical products. This year, Bioiberica’s Joint healthcare division and Heparin business unit had their own booth that presented their pharmaceutical active ingredients: chondroitin sulphate, glucosamine, hyaluronic acid, and heparin.
The CPhl Russia fair is a unique opportunity to establish strategic contacts with the leading pharmaceutical firms in Russia. Their market is growing at a 10 percent annual rate, and, according to the fair’s organization, they expect to reach 25 billion dollars by 2018. After only two editions, the numbers of exhibitors and visitors have tripled since last year.
Bioiberica would like to convey their appreciation to all visitors that came to our booth.
Related News
On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs